DNA image cytometry predicts disease outcome in stage II colorectal carcinoma

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 99-106

  Buhmeida, Abdelbaset ^a   Hilska, M ^a   Elzagheid, A ^b   Laato, M ^a   Collan, Y ^a   Syrjanen K ^a   Pyrhonen S ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b AL ARAB MEDICAL UNIVERSITY   (Libyan Arab Jamahiriya)

Author keywords

Adjuvant therapy; Dna cytometry; Prognosis; Stage II colorectal cancer

Indexed keywords

CELL NUCLEUS DNA;

ADULT; AGE DISTRIBUTION; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; COLON CARCINOMA; COLORECTAL CARCINOMA; COMPUTER ANALYSIS; DISEASE FREE SURVIVAL; DNA CONTENT; DNA DETERMINATION; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE CYTOMETRY; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOMA; TUMOR VOLUME;

AGED; ANEUPLOIDY; CELL NUCLEUS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HUMANS; IMAGE CYTOMETRY; MALE; NEOPLASM STAGING;

EID: 61449219093     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gatta G, Faivre J, Capocaccia R and Ponz de Leon M: Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 34: 2176-2183, 1998.
2. Repetto L, Venturino A, Fratino L, Serraino D, Troisi G, Gianni W and Pietropaolo M: Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39: 870-880, 2003.
3. Wymenga AN, Slaets JP and Sleijfer DT: Treatment of cancer in old age, shortcomings and challenges. Neth J Med 59: 259-266, 2001.
4. Franceschi S and La Vecchia C: Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 39: 219-226, 2001.
5. Walker J and Quirke P: Biology and genetics of colorectal cancer. Eur J Cancer 37(Suppl 7): S163-172, 2001.
6. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
7. Venook A: Status of adjuvant chemotherapy for stage II colon cancer. Proc. of ASCO Meeting, June 5-8 2004, pp. 81.184.
8. Graziano F and Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 14: 1026-1038, 2003.
9. Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J and Iacopetta B: Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64: 259-265, 2003.
10. Di Fabio F, Nascimbeni R, Villanacci, V, Baronchelli C, Bianchi D, Fabbretti G, Casella C and Salerni B: Prognostic variables for cancer-related survival in node-negative colorectal carcinomas. Dig Surg 21: 128-133, 2004.
11. Sobrero A: Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol 7: 515-516, 2006.
12. Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M and Kaufman DS: Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? Cancer J Sci Am 5: 242-247, 1999.
13. Haydon A: Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J 33: 119-124, 2003.
14. Buyse M and Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28: 20-24, 2001.
15. Buhmeida A, Algars A, Ristamaki R, Collan Y, Syrjanen K and Pyrhonen S: Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma. Anticancer Res 26: 455-462, 2006.
16. Hedley DW, Friedlander ML and Taylor IW: Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 6: 327-333, 1985.
17. Gaub J, Auer G and Zetterberg A: Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. Exp Cell Res 92: 323-332, 1975.
18. Bohnhoff GL: Setting up proper illumination on your microscope. Am J Med Technol 45: 650-651, 1979.
19. Buhmeida A, Algars A, Ristamaki R, Collan Y, Syrjanen K and Pyrhonen S: DNA image cytometry is a useful adjunct tool in the prediction of disease outcome in patients with stage II and stage III colorectal cancer. Oncology 70: 427-437, 2006.
20. Silvestrini R: Relevance of DNA-ploidy as a prognostic instrument for solid tumors. Ann Oncol 11: 259-261, 2000.
21. Scott NA, Wieand HS, Moertel CG, Cha SS, Beart RW and Lieber MM: Colorectal cancer. Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 122: 1375-1379, 1987.
22. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman HM, Cha SS, Wieand HS, Katzmann JA, Paulsen JK and Moertel CG: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68: 879-888, 1991.
23. Lanza G, Gafa R, Santini A, Maestri I, Dubini A, Gilli G and Cavazzini L: Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 82: 49-59, 1998.
24. Zarbo RJ, Nakhleh RE, Brown RD, Kubus JJ, Ma CK and Mackowiak P: Prognostic significance of DNA ploidy and proliferation in 309 colorectal carcinomas as determined by two-color multiparametric DNA flow cytometry. Cancer 79: 2073-2086, 1997.
25. Tonouchi H, Matsumoto K, Kinoshita T, Itoh H and Suzuki H: Prognostic value of DNA ploidy patterns of colorectal adenocarcinoma: univariate and multivariate analysis. Dig Surg 15: 687-692, 1998.
26. Bufill JA: Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113: 779-788, 1990.
27. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B and Hamilton SR: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213-221, 1994.
28. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48, 1994.
29. Bosari S, Lee AK, Wiley BD, Heatley GJ and Silverman ML: Flow cytometric and image analyses of colorectal adenocarcinomas. A comparative study with clinical correlations. Am J Clin Pathol 99: 187-194, 1993.
30. Lanza G Jr, Maestri I, Ballotta MR, Dubini A and Cavazzini L: Relationship of nuclear DNA content to clinicopathologic features in colorectal cancer. Mod Pathol 7: 161-165, 1994.
31. Delattre O, Olschwang S, Law DJ, Melot T, Remvikos Y, Salmon RJ, Sastre X, Validire P, Feinberg AP and Thomas G: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 2: 353-356, 1989.
32. Offerhaus GJ, De Feyter EP, Cornelisse CJ, Tersmette KW, Floyd J, Kern SE, Vogelstein B and Hamilton SR: The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 102: 1612-1619, 1992.
33. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO et al: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53: 5849-5852, 1993.
34. Bocker T, Schlegel J, Kullmann F, Stumm G, Zirngibl H, Epplen JT and Ruschoff J: Genomic instability in colorectal carcinomas: comparison of different evaluation methods and their biological significance. J Pathol 179: 15-19, 1996.
35. Johnston P, Mulligan K, Kay E, Black J, Moore S, Mc Dermott U, Wilson R and Harkin D: A genetic signature of relapse in stage II colorectal cancer derived from formalin-fixed paraffin-embedded tissue (FFPE) tissue using a unique disease-specific colorectal array. Proc. of ASCO Annual Meeting, Chigaco USA, 2006.
36. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ and Tollenaar RA: The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29: 387-398, 2007.
37. Sinicrope FA, Rego RL, Hailing KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN and Witzig TE: Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131: 729-737, 2006.
38. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE and Thibodeau SN: Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 101: 2818-2825, 2006.